Related Experiment Video

Updated: Dec 12, 2025

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.7K

Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases

JianPing Wu1, WeiLin Mao1

  • 1Department of Clinical Laboratory, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province 310003, China.

Disease Markers
|August 11, 2020
PubMed

Insights

New serum biomarkers offer simple, cost-effective methods for assessing liver disease severity and prognosis in Hepatitis B Virus (HBV)-related liver diseases. These models provide valuable clinical insights beyond traditional scoring systems.

Area of Science:

  • Hepatology
  • Biomarker Discovery
  • Liver Disease Prognosis

Background:

  • Hepatitis B Virus (HBV)-related liver diseases require accurate severity stratification and prognosis assessment.
  • Traditional scoring systems exist but may be complex or costly.
  • Serum biomarkers are emerging as promising tools for evaluating liver conditions.

Purpose of the Study:

  • To review nine popular serum biomarkers and their models for HBV-related liver diseases.
  • To highlight their utility as diagnostic and prognostic indexes.
  • To compare their advantages over traditional scoring systems.

Main Methods:

  • Literature review of recent studies on serum biomarkers.
  • Focus on nine specific biomarkers: cystatin C, homocysteine, C-reactive protein (CRP), CRP to albumin ratio, AST to platelet ratio index (APRI), FIB-4, GGT to platelet ratio, ALB to bilirubin score, and GGT to albumin ratio.
  • Analysis of diagnostic and prognostic performance.

Main Results:

  • Nine serum biomarkers and their models show significant clinical interest.
  • These biomarkers are easily acquired, simple to use, and relatively inexpensive.
  • They demonstrate potential as effective diagnostic and prognostic tools for HBV-related liver diseases.

Conclusions:

  • Serum biomarkers represent a valuable, accessible approach for managing HBV-related liver diseases.
  • These biomarkers offer a practical alternative or adjunct to traditional prognostic models.
  • Further research supports their role in clinical decision-making for liver disease patients.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

13.8K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
106
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
185
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
133